Materia, a Canadian processor and distributor of medical cannabis and CBD wellness products, announced that its wholly owned subsidiary Materia Malta has received its Licence for the Production of Cannabis for Medicinal and Research Purposes from the Malta Medicines Authority.

This means that Materia Malta can begin commercially producing and exporting medical cannabis.

Deepak Anand / LinkedIn

“We are delighted to be fully licensed and to begin generating revenues from our Malta facility,” Materia CEO Deepak Anand said.

“I’d like to congratulate our entire team for helping realise our vision of a state-of-the-art processing facility, especially in working through the circumstances presented by the pandemic over the last 18 months,” Mr Anand continued.

Materia Malta’s facility has an annual throughput capacity of 6,000kg, representing a potential sale value of €36 million.

“We are delighted to see Materia achieve this milestone,” Malta Enterprise CEO Kurt Farrugia said.

Kurt Farrugia
Kurt Farrugia / LinkedIn

“We have been working closely with Materia since the beginning and the calibre of the team exemplifies the type of company we are proud to support here in Malta. We fully expect Materia to be one of the industry’s long-term leaders,” Mr Farrugia continued.

Materia Malta has already begun the process of importing its first batch of raw material for commercial production and will begin fulfilment of its supply commitments imminently.

Related

Charles Xuereb / Trident Estates Annual Report

Firms not offering flexibility find it difficult to recruit and retain employees, says Trident Estates CEO

30 May 2024
by Fabrizio Tabone

Charles Xuereb notes that the office environment has an impact on corporate culture and lifestyles tenants want to promote.

‘Technology is changing at a rapid pace, so staying at the forefront means we need to adapt’ – BMIT CEO

30 May 2024
by Helena Grech

As the leading local technology company shares its financial results for 2023, CEO Christian Sammut attests that forward-looking plans for ...

Medserv and Regis ‘have forged a powerful alliance,’ says CEO

30 May 2024
by Robert Fenech

The company is celebrating 50 years from the founding of Medserv

‘Past year was predominantly marked by growing competitive pressures,’ says Farsons CEO

30 May 2024
by Fabrizio Tabone

During the financial year ended 31st January 2024, Farsons Group’s pre-tax profit rose by 4.9% to €16.1 million.

Close Bitnami banner
Bitnami